ClinicalTrials.gov
ClinicalTrials.gov Menu

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations (PMVS-P)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02693730
Recruitment Status : Recruiting
First Posted : February 29, 2016
Last Update Posted : February 29, 2016
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Emeran Mayer, MD, University of California, Los Angeles

Brief Summary:
The purpose of this research study is to improve the understanding of irritable bowel syndrome (IBS) and its underlying cause. The investigators will use magnetic resonance imaging (MRI) to observe differences in the brain between people diagnosed with IBS compared to healthy controls and people with ulcerative colitis, a disease group that has already been characterized. By doing this correlative and comparative study, the investigators hope to gain knowledge on IBS in order to keep the field moving in the right direction and becoming one step closer to discovering effective treatments.

Condition or disease
Irritable Bowel Syndrome Ulcerative Colitis Inflammatory Bowel Disease

Detailed Description:

Despite recent breakthroughs in research, irritable bowel syndrome (IBS) lacks a comprehensive mechanistic characterization. While the symptoms of this gastroenterological disorder have been described, the overall assessment of IBS has not led to sufficient treatment and management plans. By moving away from an over-reliance on a symptom-based approach and shifting towards a mechanism-based approach, investigators will be more knowledgeable as they attempt to address the disease. In order to accomplish this, the investigators will work with different patient subgroups, specifically IBS subjects, healthy controls (HCs), and disease control groups such as ulcerative colitis (UC). This will allow for the comparison of significant genetic, social, biological, and neurological findings between subgroups, which will help investigators grasp the differences present in people who suffer from IBS.

The investigators will approach the study in a couple different ways to characterize IBS in the best possible manner. Blood samples and MRI brain images will be collected so that the genetic and neurological factors associated with IBS can be explored. Given the highly interactive nature of the biological systems within the body, the investigators plan to explore the interaction between the brain and the immune system as well as the brain and the gut. In doing so, specific genes that contribute to IBS, as well as changes in the brain that contribute to or result from IBS, can be further scrutinized.Additionally, the immune system's influence on the brain in IBS patients can be compared to healthy controls or UC. All of this information will contribute to therapeutic studies in the future as investigators continue to develop both diagnostic tools and treatments for IBS patients.

Conducting this study necessitates the use of human subjects for research purposes. In total, the investigators will recruit 120 IBS subjects, 70 age-matched HCs, and 100 UC subjects. During the initial screening visit, the subject will complete a physical examination, a short psychological evaluation (MINI+), a pressure & heat sensitivity test, a quick blood draw, and a set of questionnaires. In total, this baseline visit will take roughly two hours.

On the second visit, the subject will return to complete more questionnaires and have their brains scanned by an MRI machine. The subject will then be disclosed of MRI safety procedures and once they are cleared, they will undergo a 60 minute scanning session with a certified MRI technician. Once this has been complete, the subject will have completed the study.

IBS female subjects that have indicated they would like to be part of the longitudinal study will return at 3 months, 6 months, 9 months, and 12 months for the same MRI procedure described above, with MR-Spectroscopy being an additional modality. They will also complete a 5 minute online survey every month for 9 months to assess their symptoms.

The Neuroimaging Core at the Center for Neurobiology of Stress will be responsible for all brain imaging analyses in years 4-5. Gene expression profiling assays and all microbiome related studies will occur at the Neuroscience Genomics Core Laboratory and the UCLA Center for Systems Biomedicine in years 4-5 as well.


Study Type : Observational
Estimated Enrollment : 290 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Perceptions and Modulations of Visceral Sensations
Study Start Date : January 2016
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Healthy Control
Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
Irritable Bowel Syndrome (IBS)
Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
Ulcerative Colitis (UC)
Clinically and histologically confirmed diagnosis of ulcerative colitis



Primary Outcome Measures :
  1. Classifying patients with IBS and Ulcerative Colitis (UC) based on their brain "signatures" obtained from structural and functional MRI scanning. [ Time Frame: MRI visit will be 45 min to 1 hour. ]
    Magnetic Resonance Imaging provides investigators with anatomical and functional images of the brain. Analytical neuroimaging tools demonstrate the unique brain properties of subjects in accordance with their conditions, referred to as brain "signatures."

  2. Global and regional brain network alterations in IBS. [ Time Frame: MRI visit will be 45 min to 1 hour. ]
    The architecture and wiring of the brain can be characterized using metrics describing the connectedness of brain regions, global and local network communication and signaling, and the contribution of each region to the network's structural integrity and information flow.

  3. Possible biological mediators of observed IBS related brain network alterations [ Time Frame: There will be a screening visit of about 1 hour with a single blood and stool sample; followed by about 40 minutes of on-line questionnaires. ]
    Proposed plausible pathophysiological mechanisms underlying structural and functional brain changes include: 1) Genetic and epigenetic factors; 2) neuroinflammation; 3) growth factor or stress-mediator induced neuroplastic changes; 4) microbiome derived metabolites.


Biospecimen Retention:   Samples With DNA

Stool samples will be collected from both IBS and IBD subjects. A full stool analysis will be performed on the stool of IBS subjects, whereas only calprotectin will be measured in the stool of IBD subjects.

Blood will be collected from IBS subjects and HCs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subject population will be made up of male and female adults between the ages of 18-60 and must fall into one of the following 3 groups: a) irritable bowel syndrome, b) ulcerative colitis, or c) healthy controls. Medical screening will be a physician or a nurse will confirm subject eligibility for the study.Subjects will be recruited from clinics and the community in and around Los Angeles Area.
Criteria

Inclusion Criteria for all IBS subjects:

  • Meet Rome III criteria for IBS
  • No red flag signs (i.e., weight loss, bloody stool, fever, anemia)

Inclusion Criteria for all UC subjects:

  • Must have UC diagnosis that is clinically & histologically confirmed

Inclusion Criteria for all subjects:

  • If woman of childbearing potential, must be willing to use contraception to avoid pregnancy during the course of the study
  • If female, negative urine pregnancy tests at Screening & MRI Visit
  • Right-handed
  • Willingness to participate in this study as evidenced by signed informed consent form
  • ambulatory outpatient (does not depend on wheelchair for mobility)
  • English is primary oral and written language

Exclusion Criteria for all subjects:

  • Major medical intervention occurring in the next 6 months or in the past 6 months
  • Presence of significant and ongoing medical problem interfering with participation
  • Presence of major psychiatric diagnosis such as schizophrenia, bipolar disorder, PTSD, or Obsessive Compulsive disorder.
  • Use of centrally acting medications that will interfere with neuroimaging testing (opiate analgesics, antidepressants).
  • Left handed due to importance of laterality in neuroimaging
  • Pregnancy or nursing
  • Claustrophobia, Ferromagnetic Implants, or other problematic issues preventing subject participation in MRI
  • Current or past history of chronic pain syndrome other than IBS in the IBS group
  • History of gastrointestinal surgery other than uncomplicated appendectomy or cholecystectomy
  • Use of investigational drugs, products, or devices within 28 days prior to screen and through study participation
  • use of steroids in the last 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02693730


Contacts
Contact: Kareem Hamadani, BS khamadani@mednet.ucla.edu
Contact: Jean Stains, RN 310-206-1758 jstains@mednet.ucla.edu

Locations
United States, California
Center for Neurobiology of Stress Recruiting
Los Angeles, California, United States, 90095
Contact: Kareem Hamadani, BS       khamadani@mednet.ucla.edu   
Contact: Jean Stains, RN    310-206-1758    jstains@mednet.ucla.edu   
Principal Investigator: Emeran Mayer, MD         
Sponsors and Collaborators
University of California, Los Angeles
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Emeran Mayer, MD University of California, Los Angeles

Additional Information:
Responsible Party: Emeran Mayer, MD, Professor and Director, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT02693730     History of Changes
Other Study ID Numbers: 2R01DK048351-15A1 ( U.S. NIH Grant/Contract )
2R01DK048351-15A1 ( U.S. NIH Grant/Contract )
First Posted: February 29, 2016    Key Record Dates
Last Update Posted: February 29, 2016
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All data will be stripped of identifiers before data sharing

Keywords provided by Emeran Mayer, MD, University of California, Los Angeles:
Inflammatory Bowel Disease
Irritable Bowel Syndrome
IBS
Ulcerative Colitis
UC
IBD
Healthy Control
HC
Visceral Pain
Gut
Neuroimaging
fMRI
resting state
structural MRI
functional MRI
diffusion tensor imaging
MR Spectroscopy

Additional relevant MeSH terms:
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Colonic Diseases, Functional
Colitis
Ulcer
Colitis, Ulcerative
Irritable Bowel Syndrome
Gastroenteritis
Pathologic Processes